EMA To Be Flexible On Best Time To Enter PRIME Scheme Regardless Of Company Size
Executive Summary
The Europe Medicines Agency is reconsidering its rules governing at which stage of drug development it permits companies to enter its PRIME scheme, but it is not yet ready for the initiative to be used for extending the indications of already approved products.